Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing dealCNBC • 12/18/24
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor AgonistBusiness Wire • 12/18/24
Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants from RSV Disease During their First RSV SeasonBusiness Wire • 12/17/24
Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with PembrolizumabBusiness Wire • 12/16/24
Merck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLCBusiness Wire • 12/16/24
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell CarcinomaBusiness Wire • 12/13/24
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost OverThe Motley Fool • 12/12/24
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 TrialBusiness Wire • 12/11/24
The Zacks Analyst Blog Alphabet, Oracle, Merck & Co, Canterbury Park and CompX InternationalZacks Investment Research • 12/11/24
MRK's Keytruda & Lynparza Combo Meets Goal in Ovarian Cancer StudyZacks Investment Research • 12/10/24
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian CancerBusiness Wire • 12/09/24
Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell LymphomaBusiness Wire • 12/08/24
Tanzania President, Merck Foundation Chairman and CEO With 15 First Ladies Inaugurate Their 11th Africa Asia Luminary 2024Business Wire • 12/05/24